Rui-Yu Chen

Title: Innovations of Rui-Yu Chen in Nuclear Medicine

Introduction

Rui-Yu Chen is a prominent inventor based in Taoyuan, Taiwan. He has made significant contributions to the field of nuclear medicine, particularly in the development of imaging agents for positron emission tomography (PET). With a total of 2 patents, his work focuses on enhancing the effectiveness and stability of radiolabeling techniques.

Latest Patents

Rui-Yu Chen's latest patents include a hexa-lactoside-triazanonane triacetic acid (NOTA) derivative and a method for radiolabeling a hexa-lactoside PET imaging agent for liver receptors using Ga-68. The hexa-lactoside-NOTA derivative is a conjugate of six chains of lactose with NOTA, achieved through a process involving a chelating agent and triethyl amine/dimethyl formamide as a solvent. The radiolabeling method he developed is notable for its high labeling efficiency, exceeding 95%, and maintaining a radiochemical purity greater than 90% even after four hours.

Career Highlights

Rui-Yu Chen is affiliated with the Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. His innovative approaches in the preparation of 6-aminohexyl lactoside-NOTA conjugates have led to increased yields and reduced impurities, making his methods suitable for large-scale production.

Collaborations

Some of his notable coworkers include Wuu-Jyh Lin and Mei-Hui Wang, who have contributed to his research endeavors.

Conclusion

Rui-Yu Chen's work in the field of nuclear medicine exemplifies the impact of innovative thinking on medical imaging technologies. His patents reflect a commitment to advancing the effectiveness of PET imaging agents, which can significantly enhance diagnostic capabilities in healthcare.